Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant lentiviral vector injection for chronic hepatitis B
- Development stage
- Unknown
- Lead developer
- Changzhi People's Hospital
- Modality
- Gene Therapies, Vaccines & Immunotherapeutics
- Administration
- Parenteral
01
Overview
Recombinant lentiviral vector injection for chronic hepatitis B is a therapeutic gene-based vaccine candidate being developed for the treatment of chronic hepatitis B virus (HBV) infection. The therapy utilizes a lentiviral vector platform to deliver HBV-specific genetic sequences into host cells, aiming to induce a robust and sustained T-cell-mediated immune response against the virus. By expressing viral antigens in vivo, the vector is designed to overcome the immune tolerance characteristic of chronic HBV infection and promote viral clearance. A Phase 0 pilot interventional study (ChiCTR2200062625) sponsored by Changzhi People's Hospital in China has been initiated to evaluate the safety, tolerability, and preliminary antiviral and immunologic activity of the injection in adults.
- Other names
- recombinant therapeutic lentiviral vector injection
02
Targets
LHBs (Hepatitis B virus large surface protein)
Beyond the preview
Go deeper on recombinant lentiviral vector injection for chronic hepatitis B.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant lentiviral vector injection for chronic hepatitis B.